Supernus Pharmaceuticals | SUPN - Assets


Supernus Pharmaceuticals reported $1.5B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
ANI Pharmaceuticals USD 1.42B 18.41M Mar/2026
Aurora Cannabis CAD 775.29M 18.43M Dec/2025
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Canopy Growth CAD 1.11B 36.35M Dec/2025
Cara Therapeutics USD 32.07M 6.95M Dec/2025
Corcept Therapeutics USD 814.88M 21.77M Mar/2026
Eisai JPY 1.45T 37.11B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Novo Nordisk DKK 559.22B 16.32B Mar/2026
Pacira USD 1.21B 56.38M Mar/2026
Perrigo USD 7.98B 551.9M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Supernus Pharmaceuticals USD 1.5B 48.08M Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026
Xeris Pharmaceuticals USD 392.01M 8.49M Mar/2026